Yes, buspirone can be safely continued in this patient with thoracic aortic aneurysm and hypertension.
Buspirone has no contraindications related to thoracic aortic aneurysm or hypertension and does not interfere with the critical blood pressure management required for TAA patients.
Key Rationale
No Cardiovascular Contraindications
The FDA label for buspirone contains no warnings or precautions regarding thoracic aortic aneurysm, aortic disease, or hypertension 1. The primary warnings focus on:
- MAOI interactions (serotonin syndrome risk)
- Serotonergic drug combinations
- CNS effects and sedation
Blood Pressure Considerations
While animal studies showed variable cardiovascular effects at high doses (oral administration reduced blood pressure in conscious rats by 14-22 mmHg at 30 mg/kg) 2, the FDA label notes these doses are "considerably greater than those which produce anxiolytic effects" and states "it is doubtful that anxiolytic doses of buspirone will produce cardiovascular alterations in patients" 2.
The critical priority for TAA management is achieving BP control <130/80 mmHg using beta-blockers and ARBs as first-line agents 3, 4. Buspirone does not interfere with these medications or compromise BP control.
No Drug Interactions with Guideline-Recommended Agents
Buspirone has no significant interactions with:
- Beta-blockers (recommended for TAA) 3
- ARBs (recommended as adjunct therapy for TAA) 3
- Other antihypertensive medications 1
The FDA label specifically documents that buspirone showed no significant pharmacokinetic interactions with diazepam or amitriptyline, and does not potentiate sedative effects of benzodiazepines 1.
Clinical Caveats
Ensure Optimal BP Control First
The primary concern is that 54.2% of TAA patients have above-target blood pressure even in specialized care settings 5. Before continuing any medication:
- Verify current BP is <130/80 mmHg
- Ensure patient is on appropriate beta-blocker therapy (Class I recommendation) 3
- Consider ARB if BP not at goal with beta-blocker alone (Class IIa recommendation) 3
Monitor for Rare Cardiovascular Effects
While not contraindicated, be aware that:
- Buspirone can cause transient bradycardia (documented in animal studies) 2, 6
- One study in heart failure patients showed buspirone was well-tolerated with no serious adverse cardiovascular events 7
- Standard anxiolytic doses (15-60 mg daily) are far below doses that produced hemodynamic changes in animal models 1, 2
Avoid Absolute Contraindications
Do not continue buspirone if patient is:
- Taking MAOIs (14-day washout required) 1
- On linezolid or IV methylene blue (serotonin syndrome risk) 1
- Taking multiple serotonergic agents without careful monitoring 1
Practical Management Algorithm
- Verify BP control: Confirm patient's BP is <130/80 mmHg on current regimen
- Optimize TAA-specific therapy: Ensure beta-blocker ± ARB is prescribed per guidelines 3
- Continue buspirone: No dose adjustment needed for TAA or hypertension
- Consistent dosing: Instruct patient to take buspirone consistently with or without food (affects bioavailability) 1
- Standard monitoring: No additional cardiovascular monitoring required beyond routine TAA surveillance
The anxiety management provided by buspirone may actually benefit overall cardiovascular health, as anxiety itself can contribute to BP elevation and medication non-adherence.